Your browser doesn't support javascript.
loading
Development of a TaqMan Array Card for Acute-Febrile-Illness Outbreak Investigation and Surveillance of Emerging Pathogens, Including Ebola Virus.
Liu, Jie; Ochieng, Caroline; Wiersma, Steve; Ströher, Ute; Towner, Jonathan S; Whitmer, Shannon; Nichol, Stuart T; Moore, Christopher C; Kersh, Gilbert J; Kato, Cecilia; Sexton, Christopher; Petersen, Jeannine; Massung, Robert; Hercik, Christine; Crump, John A; Kibiki, Gibson; Maro, Athanasia; Mujaga, Buliga; Gratz, Jean; Jacob, Shevin T; Banura, Patrick; Scheld, W Michael; Juma, Bonventure; Onyango, Clayton O; Montgomery, Joel M; Houpt, Eric; Fields, Barry.
Afiliação
  • Liu J; Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, Virginia, USA.
  • Ochieng C; Center for Global Health Research, Kenya Medical Research Institute, Nairobi, Kenya.
  • Wiersma S; Centers for Disease Control and Prevention, Center for Global Health, Division of Global Health Protection, Dar es Salaam, Tanzania.
  • Ströher U; Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Division of High Consequence Pathogens and Pathology, Atlanta, Georgia, USA.
  • Towner JS; Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Division of High Consequence Pathogens and Pathology, Atlanta, Georgia, USA.
  • Whitmer S; Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Division of High Consequence Pathogens and Pathology, Atlanta, Georgia, USA.
  • Nichol ST; Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Division of High Consequence Pathogens and Pathology, Atlanta, Georgia, USA.
  • Moore CC; Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, Virginia, USA.
  • Kersh GJ; Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Division of Vector Borne Diseases, Atlanta, Georgia, USA.
  • Kato C; Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Division of Vector Borne Diseases, Atlanta, Georgia, USA.
  • Sexton C; Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Division of Vector Borne Diseases, Atlanta, Georgia, USA.
  • Petersen J; Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Division of Vector Borne Diseases, Atlanta, Georgia, USA.
  • Massung R; Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Division of High Consequence Pathogens and Pathology, Atlanta, Georgia, USA.
  • Hercik C; Georgetown University, Washington, DC, USA.
  • Crump JA; Division of Infectious Diseases and International Health, Duke University, Durham, North Carolina, USA Centre for International Health, University of Otago, Dunedin, New Zealand.
  • Kibiki G; Kilimanjaro Clinical Research Institute, Moshi, Tanzania.
  • Maro A; Kilimanjaro Clinical Research Institute, Moshi, Tanzania.
  • Mujaga B; Kilimanjaro Clinical Research Institute, Moshi, Tanzania.
  • Gratz J; Kilimanjaro Clinical Research Institute, Moshi, Tanzania.
  • Jacob ST; Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
  • Banura P; Masaka Regional Referral Hospital, Masaka, Uganda.
  • Scheld WM; Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, Virginia, USA.
  • Juma B; Centers for Disease Control and Prevention, Center for Global Health, Division of Global Health Protection, Nairobi, Kenya.
  • Onyango CO; Centers for Disease Control and Prevention, Center for Global Health, Division of Global Health Protection, Nairobi, Kenya.
  • Montgomery JM; Centers for Disease Control and Prevention, Center for Global Health, Division of Global Health Protection, Nairobi, Kenya Centers for Disease Control and Prevention, Center for Global Health, Division of Global Health Protection, Atlanta, Georgia, USA.
  • Houpt E; Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, Virginia, USA erh6k@virginia.edu bsf2@cdc.gov.
  • Fields B; Centers for Disease Control and Prevention, Center for Global Health, Division of Global Health Protection, Nairobi, Kenya Centers for Disease Control and Prevention, Center for Global Health, Division of Global Health Protection, Atlanta, Georgia, USA erh6k@virginia.edu bsf2@cdc.gov.
J Clin Microbiol ; 54(1): 49-58, 2016 Jan.
Article em En | MEDLINE | ID: mdl-26491176
ABSTRACT
Acute febrile illness (AFI) is associated with substantial morbidity and mortality worldwide, yet an etiologic agent is often not identified. Convalescent-phase serology is impractical, blood culture is slow, and many pathogens are fastidious or impossible to cultivate. We developed a real-time PCR-based TaqMan array card (TAC) that can test six to eight samples within 2.5 h from sample to results and can simultaneously detect 26 AFI-associated organisms, including 15 viruses (chikungunya, Crimean-Congo hemorrhagic fever [CCHF] virus, dengue, Ebola virus, Bundibugyo virus, Sudan virus, hantaviruses [Hantaan and Seoul], hepatitis E, Marburg, Nipah virus, o'nyong-nyong virus, Rift Valley fever virus, West Nile virus, and yellow fever virus), 8 bacteria (Bartonella spp., Brucella spp., Coxiella burnetii, Leptospira spp., Rickettsia spp., Salmonella enterica and Salmonella enterica serovar Typhi, and Yersinia pestis), and 3 protozoa (Leishmania spp., Plasmodium spp., and Trypanosoma brucei). Two extrinsic controls (phocine herpesvirus 1 and bacteriophage MS2) were included to ensure extraction and amplification efficiency. Analytical validation was performed on spiked specimens for linearity, intra-assay precision, interassay precision, limit of detection, and specificity. The performance of the card on clinical specimens was evaluated with 1,050 blood samples by comparison to the individual real-time PCR assays, and the TAC exhibited an overall 88% (278/315; 95% confidence interval [CI], 84% to 92%) sensitivity and a 99% (5,261/5,326, 98% to 99%) specificity. This TaqMan array card can be used in field settings as a rapid screen for outbreak investigation or for the surveillance of pathogens, including Ebola virus.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Transmissíveis / Surtos de Doenças / Técnicas de Diagnóstico Molecular / Febre de Causa Desconhecida / Reação em Cadeia da Polimerase em Tempo Real Tipo de estudo: Diagnostic_studies / Evaluation_studies / Prognostic_studies / Screening_studies Limite: Adult / Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Transmissíveis / Surtos de Doenças / Técnicas de Diagnóstico Molecular / Febre de Causa Desconhecida / Reação em Cadeia da Polimerase em Tempo Real Tipo de estudo: Diagnostic_studies / Evaluation_studies / Prognostic_studies / Screening_studies Limite: Adult / Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article